References
- 1. Gangat N, Patnaik M, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016; 91(1): 76-89.
- 2. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology. 1974; 30(5): 405-22.
- 3. Kaminskas E, Farrell A, Wang Y, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10(3):176-82.
- 4. Estey E. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013; 27(9):1803-12.
- 5. Micheva I, Dimitrova S, Efraim M, et al. Outcome after azacitidine treatment in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia in the Clinic of Hematology at St. Marina University Hospital, Varna. Scripta Scientifica Medica. 2018; 50(1):31-35
- 6. Varbanova V, Anastasova-Postadzhiyan A, Nedeva A, et al. Outcome After Azacitidine Treatment in Patients with High Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data). Acta Medica Bulgarica. 2020;47:38-43.
- 7. Tendas A, Cupelli L, Siniscalchi A, et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach. Mediterr J Hematol Infect Dis. 2014;6(1): e2014020.
- 8. Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502-13.
- 9. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007; 21(9): 1937-44.
- 10. Gore S, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66(12): 6361-9.
- 11. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-9.
- 12. Gangat N, Patnaik M, Begna K, et al. Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. Mayo Clin Proc. 2015;90(12):1623-38.
- 13. Wiktor A, Rybicki B, Piao ZS, et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer. 2000;27(1):11-6.
- 14. Mufti G, Gore S, Santini V, et al. Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen. Blood. 2009;114(22):1755.
- 15. Fenaux P, Mufti G. J, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
- 16. Dohner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546-2557.
- 17. Usami E, Kimura M, Takenaka S et al. Continuity and efficacy of real-world use of azacitidine. Pharmazie. 2020;75(4):154-158.
- 18. Muller-Thomas C, Schuster T, Peschel C, et al. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol. 2009;88(3):213-9.
- 19. Cseh A.M, Niemeyer C. M, Yoshimi A et al. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group. Br J Haematol. 2016;172(6):930-6.
- 20. Xie M, Jiang Q, Xie Y et al. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Clin Lymphoma Myeloma Leuk. 2015;15(1):22-8.